首页> 美国卫生研究院文献>Drug Delivery >Self-assembling HA/PEI/dsRNA-p21 ternary complexes for CD44 mediated small active RNA delivery to colorectal cancer
【2h】

Self-assembling HA/PEI/dsRNA-p21 ternary complexes for CD44 mediated small active RNA delivery to colorectal cancer

机译:CD44介导的CD44介导的小型活性RNA递送至结直肠癌自组装HA / PEI / DSRNA-P21络合物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our previous work proved that sequence specific double strand RNA (dsRNA-p21) effectively activated p21 gene expression of colorectal cancer (CRC) cells and consequently suppressed CRC growth. However, efficient delivery system is a significant challenge to achieve sufficient therapy. In this study, a self-assembled HA/PEI/dsRNA-p21 ternary complex (TC-dsRNA-p21) was developed for the tumor-target delivery of dsRNA-p21 into CRC cells. Hyaluronic acid (HA) was introduced to shield the PEI/dsRNA-p21 binary complexes (BC-dsRNA-p21) for reducing the cytotoxicity of PEI and for increasing the tumor-targeted intracellular uptake by cancer cells through HA-CD44 mediated endocytosis. Comparing to the BC-dsRNA-p21, the TC-dsRNA-p21 showed increase in size, decrease in zeta potential, low cytotoxicity as well as high stability in physiological conditions due to the anionic shielding. Confocal microscopy analysis and flow cytometry confirmed that TC-dsRNA-p21 had high transfection efficiency in the CD44-abundant Lovo cells, as compared with binary complex. In vitro physiological experiment showed that, comparing to the control group, the TC-dsRNA-p21 effectively activated the expression of p21 mRNA and P21 protein, causing blockage of cell cycle at G0/G1 phase and suppression of cancer cell proliferation as well as colony formation. Furthermore, in vivo distribution experiment demonstrated that the TC-dsRNA-p21 could effectively accumulate at rectal wall for up to 10 h, following in situ application. These findings indicated that TC-dsRNA-p21 might hold great potential for delivering dsRNA-p21 to treat CRC.
机译:我们以前的工作证明,序列特异性双链RNA(DSRNA-P21)有效地激活了结直肠癌(CRC)细胞的P21基因表达,从而抑制了CRC生长。然而,有效的交付系统是实现足够疗法的重大挑战。在该研究中,开发了一种自组装的HA / PEI / DSRNA-P21三元复合物(TC-DSRNA-P21),用于DSRNA-P21中的肿瘤 - 靶递送到CRC细胞中。引入透明质酸(HA)以屏蔽PEI / DSRNA-P21二元络合物(BC-DSRNA-P21)以降低PEI的细胞毒性,并通过HA-CD44介导的内吞作用增加癌细胞的肿瘤靶向细胞内摄取。与BC-DSRNA-P21相比,TC-DSRNA-P21显示尺寸的增加,Zeta电位降低,低细胞毒性以及由于阴离子屏蔽引起的生理条件下的高稳定性。与二元络合物相比,共聚焦显微镜分析和流式细胞术证实,TC-DSRNA-P21在CD44 - 丰富的Lovo细胞中具有高转染效率。体外生理实验表明,与对照组相比,TC-DSRNA-P21有效地活化了P21 mRNA和P21蛋白的表达,导致细胞周期堵塞在G0 / G1相和抑制癌细胞增殖以及殖民地形成。此外,在体内分布实验中表明,TC-DSRNA-P21可以在直肠壁上有效地积聚,高达10小时,以便在原位施用之后。这些发现表明,TC-DSRNA-P21可能具有赋予DSRNA-P21治疗CRC的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号